{"id":215758,"date":"2024-10-17T10:03:05","date_gmt":"2024-10-17T14:03:05","guid":{"rendered":"https:\/\/www.breakthrought1d.org\/sobre\/nuestra-historia\/"},"modified":"2026-11-13T13:41:03","modified_gmt":"2026-11-13T18:41:03","slug":"nuestra-historia","status":"publish","type":"page","link":"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/","title":{"rendered":"Nuestra historia"},"content":{"rendered":"\n<div class=\"page-header alignfull wp-block-jdfr-page-header\">\n\t<div class=\"page-header__inner-container\">\n\t\t\n<nav id=\"breadcrumbs\" class=\"site-breadcrumbs alignfull\" aria-label=\"Breadcrumbs\">\n\t<ul class=\"site-breadcrumbs__inner\"><li class=\"breadcrumb-item\"><a href=\"https:\/\/www.breakthrought1d.org\/es\/\">Inicio<\/a><\/li><li class=\"site-breadcrumbs__separator\"><?xml version=\"1.0\"?>\n<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"9.143\" height=\"16\" fill=\"currentColor\" viewBox=\"0 0 9.143 16\" aria-hidden=\"true\"><path d=\"M1.143 16a1.143 1.143 0 0 1-.808-1.951L6.384 8 .335 1.951A1.143 1.143 0 0 1 1.951.335l6.857 6.857a1.143 1.143 0 0 1 0 1.616l-6.857 6.857a1.14 1.14 0 0 1-.808.335\"\/><\/svg>\n<\/li><li class=\"breadcrumb-item\" aria-current=\"page\" tabindex=\"0\" role=\"text\" aria-label=\"P\u00e1gina actual: \"><\/li><\/ul><\/nav>\n\n\t\t<div class=\"page-header__content\">\n\t\t\t<h1 class=\"page-header__title\">Nuestra historia<\/h1>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n<div class=\"wp-block-group alignfull has-gradient is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e50f5278 wp-block-columns-is-layout-flex has-2-columns\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<h2 id=\"introduction-b-simple-large-text-lorem-ipsum-dolor-sit-amet-consectetur-adipiscing-elit-sed-do-eiusmod-tempor-incididunt-ut-labore-et-dolore-magna-aliqua-ut-enim-ad-minim-veniam-quis-nostrud\" class=\"wp-block-heading\">Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. <\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:15%\"><\/div>\n<\/div>\n<\/div>\n<section class=\"wp-block-jdrf-timeline\">\n\t\t\t<h2 class=\"wp-block-jdrf-timeline__title\">Una cronolog\u00eda de nuestros principales logros<\/h2>\n\t\n\t\n\t<div class=\"wp-block-jdrf-timeline__entries\">\n\t\t\n<div class=\"wp-block-jdrf-timeline-year\">\n\t\t\t<h3 class=\"wp-block-jdrf-timeline-year__year\">los a\u00f1os 70<\/h3>\n\t\n\t<div class=\"wp-block-jdrf-timeline-year__list\">\n\t\t\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1521\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-scaled.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Lee Ducat (L) and Carole Lurie (R) Meet With a Legislator\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-scaled.jpg 2560w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-800x475.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-200x119.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-768x456.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-1536x912.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-2048x1217.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-400x238.jpg 400w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-1200x713.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/03\/LeeandCarol-1600x950.jpg 1600w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1970<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Creaci\u00f3n de la Fundaci\u00f3n para la Diabetes Juvenil<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">La Fundaci\u00f3n para la Diabetes Juvenil, ahora Breakthrough T1D, est\u00e1 fundada por Lee Ducat, Carol Lurie, Erwin Lurie y un grupo de padres cuyos hijos tienen T1D. Su convicci\u00f3n es clara: mediante la investigaci\u00f3n, la T1D puede curarse y se curar\u00e1. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/the-jdrf-journey-where-it-all-began\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tLeer m\u00e1s sobre Donde comenz\u00f3 nuestro viaje\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1976<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Creaci\u00f3n de la prueba de hemoglobina A1c (HbA1c)<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">El Dr. Anthony Cerami, investigador financiado por Breakthrough T1D, demuestra que la hemoglobina puede utilizarse para medir m\u00e1s eficazmente la gesti\u00f3n del nivel de glucosa en sangre. Este descubrimiento condujo a la creaci\u00f3n de la prueba de hemoglobina A1c (HbA1c), que ahora es la norma de oro para la aprobaci\u00f3n de f\u00e1rmacos para la diabetes. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/jdrf-report-how-hba1c-came-1976\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el origen de la HbA1c\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/div>\n\n\n<div class=\"wp-block-jdrf-timeline-year\">\n\t\t\t<h3 class=\"wp-block-jdrf-timeline-year__year\">los a\u00f1os 80<\/h3>\n\t\n\t<div class=\"wp-block-jdrf-timeline-year__list\">\n\t\t\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1982<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Crean insulina humana modificada gen\u00e9ticamente<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Un gran avance cient\u00edfico financiado por la T1D conduce al desarrollo de la insulina modificada gen\u00e9ticamente: la primera prote\u00edna humana clonada y fabricada mediante ingenier\u00eda gen\u00e9tica. Se comercializa con el nombre de Humulin y recibe la aprobaci\u00f3n de la FDA. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/100-100-genetically-engineered-human-insulin-created\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el desarrollo de Humulin\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1128\" height=\"862\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/MiniMed-Insulin-Pump.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Minimed Insulin Pump\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/MiniMed-Insulin-Pump.jpg 1128w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/MiniMed-Insulin-Pump-300x229.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/MiniMed-Insulin-Pump-1024x783.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/MiniMed-Insulin-Pump-768x587.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/MiniMed-Insulin-Pump-800x611.jpg 800w\" sizes=\"auto, (max-width: 1128px) 100vw, 1128px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1983<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Primera bomba de insulina disponible en el mercado<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">La primera bomba de insulina ha sido desarrollada y comercializada por Medtronic, uno de los socios industriales de Breakthrough T1D.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/manejo-diario\/tecnologia-dt1\/sistemas-automaticos-de-administracion-de-insulina-y-bombas-de-insulina\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre las bombas de insulina\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1989<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Primer trasplante de islotes en humanos<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">El revolucionario investigador Paul Lacey, doctor en medicina y doctorado en T1D, realiza el primer trasplante de islotes en humanos.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/explora-investigacion\/cura-dt1\/terapias-celulares\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tExplora nuestra investigaci\u00f3n en terapias celulares\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/div>\n\n\n<div class=\"wp-block-jdrf-timeline-year\">\n\t\t\t<h3 class=\"wp-block-jdrf-timeline-year__year\">los a\u00f1os 90<\/h3>\n\t\n\t<div class=\"wp-block-jdrf-timeline-year__list\">\n\t\t\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"622\" height=\"460\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/05\/EyeDisease-Then.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Patient receiving a diabetic eye exam\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/05\/EyeDisease-Then.jpg 622w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/05\/EyeDisease-Then-200x148.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/05\/EyeDisease-Then-400x296.jpg 400w\" sizes=\"auto, (max-width: 622px) 100vw, 622px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1992<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Se establece una conexi\u00f3n entre los niveles elevados de az\u00facar en sangre y la enfermedad ocular diab\u00e9tica<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Una investigaci\u00f3n pionera sobre la T1D establece la relaci\u00f3n causal entre la enfermedad ocular diab\u00e9tica y los niveles elevados de az\u00facar en sangre. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/100-100-ending-diabetic-eye-disease-forever\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre nuestra investigaci\u00f3n en la enfermedad ocular diab\u00e9tica\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1707\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-scaled.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Image of U.S. Capitol Building\" style=\"object-position: 50% 93%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-scaled.jpg 2560w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-1536x1024.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-2048x1365.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-800x533.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/404_Page_Secondary_Page_Links_OurAdvocacyStrategy-1200x800.jpg 1200w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1997<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Creaci\u00f3n del Programa Especial de Diabetes<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">El Congreso crea el Programa Especial de Diabetes (PDE) para hacer frente a las limitaciones de la investigaci\u00f3n sobre la diabetes debidas a la falta de financiaci\u00f3n. El SDP ha sido fundamental para las terapias que actualmente mejoran la vida de los enfermos de T1D y financia la investigaci\u00f3n de futuras curas. Hasta abril de 2024, el SDP ha dedicado m\u00e1s de 3.500 millones de d\u00f3lares a la investigaci\u00f3n de la T1D.  <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/explora-defensa\/programa-especial-diabetes\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el Programa Especial de Diabetes\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"480\" height=\"320\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Breakthrough T1D Children&#039;s Congress and Mary Tyler Moore\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480.jpg 480w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480-200x133.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480-400x267.jpg 400w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480-150x100.jpg 150w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480-291x194.jpg 291w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2017\/01\/photo_-_mary-tyler-moore-jdrf-childrens-congress-2005-home1_480-450x300.jpg 450w\" sizes=\"auto, (max-width: 480px) 100vw, 480px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">1999<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Primer Congreso Infantil<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Dirigido por Mary Tyler Moore, el primer Congreso Infantil Breakthrough T1D (antes Congreso Infantil de la JDRF) permite a los ni\u00f1os con T1D compartir sus experiencias con los miembros del Congreso y abogar por la financiaci\u00f3n federal de la investigaci\u00f3n de la T1D.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/cc.breakthrought1d.org\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el Congreso Infantil\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/div>\n\n\n<div class=\"wp-block-jdrf-timeline-year\">\n\t\t\t<h3 class=\"wp-block-jdrf-timeline-year__year\">A\u00f1os 2000<\/h3>\n\t\n\t<div class=\"wp-block-jdrf-timeline-year__list\">\n\t\t\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2000<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Desarrollo del Protocolo de Edmonton<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Los investigadores de Breakthrough T1D desarrollan el Protocolo de Edmonton para el trasplante de islotes, que mejora enormemente la tasa de \u00e9xito del trasplante de c\u00e9lulas productoras de insulina en personas con T1D.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/?p=131192\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el Protocolo de Edmonton\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"781\" height=\"543\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/12\/APSystem.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Illustration of first Artificial Pancreas System\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/12\/APSystem.jpg 781w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/12\/APSystem-200x139.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/12\/APSystem-768x534.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/12\/APSystem-400x278.jpg 400w\" sizes=\"auto, (max-width: 781px) 100vw, 781px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2006<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Consorcio del P\u00e1ncreas Artificial<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Breakthrough T1D lanza el Consorcio del P\u00e1ncreas Artificial, que re\u00fane a los mejores cient\u00edficos de los sectores p\u00fablico, privado y acad\u00e9mico para trabajar en colaboraci\u00f3n en el desarrollo y suministro de sistemas de p\u00e1ncreas artificial (PA).<\/p>\n\t\t\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2007<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Se pone en marcha la Red de Donantes de \u00d3rganos Pancre\u00e1ticos con Diabetes<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Breakthrough T1D pone en marcha la Red de Donantes de \u00d3rganos Pancre\u00e1ticos con Diabetes (nPOD), el \u00fanico banco de tejidos del mundo para donantes de p\u00e1ncreas y tejidos relacionados de personas con T1D o riesgo de padecerla. La investigaci\u00f3n de esta iniciativa ha cambiado fundamentalmente nuestra comprensi\u00f3n de la T1D. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/?p=25221\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre nPOD\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"624\" height=\"540\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/Boy-with-CGM.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Young boy with type 1 diabetes wearing a continuous glucose monitor (CGM)\" style=\"object-position: 49% 11%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/Boy-with-CGM.jpg 624w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/Boy-with-CGM-300x260.jpg 300w\" sizes=\"auto, (max-width: 624px) 100vw, 624px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2008<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Uso m\u00e1s amplio del MCG<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Un ensayo cl\u00ednico financiado por Breakthrough T1D demuestra la eficacia de los monitores continuos de glucosa (MCG) para ayudar a controlar el az\u00facar en sangre, con niveles m\u00e1s bajos de HbA1c y menores tasas de hipoglucemia grave. Esto conduce a la cobertura por parte de los pagadores de estos dispositivos que cambian la vida. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/manejo-diario\/tecnologia-dt1\/monitores-continuos-de-glucosa\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre los monitores de glucosa continuos\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/div>\n\n\n<div class=\"wp-block-jdrf-timeline-year\">\n\t\t\t<h3 class=\"wp-block-jdrf-timeline-year__year\">los a\u00f1os 2010<\/h3>\n\t\n\t<div class=\"wp-block-jdrf-timeline-year__list\">\n\t\t\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1707\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-scaled.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Woman Receiving Treatment for Diabetic Macular Edema\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-scaled.jpg 2560w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-800x533.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-200x133.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-1536x1024.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-2048x1365.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-400x267.jpg 400w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-1200x800.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/04\/GettyImages-1398349886-1600x1067.jpg 1600w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2010<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Aprobaci\u00f3n de Lucentis por la FDA para el tratamiento del edema macular diab\u00e9tico<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Un gran avance Los investigadores de la T1D demuestran en ensayos cl\u00ednicos que un f\u00e1rmaco llamado Lucentis es eficaz contra la enfermedad ocular diab\u00e9tica. Recibe la aprobaci\u00f3n de la FDA, lo que lo convierte en el primer f\u00e1rmaco aprobado para la enfermedad ocular diab\u00e9tica y el primer tratamiento nuevo en 25 a\u00f1os. <\/p>\n\t\t\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2012<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">La FDA publica una gu\u00eda sobre sistemas AP<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">La FDA publica su gu\u00eda final sobre los sistemas de AP, basada en las recomendaciones de Breakthrough T1D, que proporciona una hoja de ruta normativa clara y razonable.<\/p>\n\t\t\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/02\/Douglas-Melton-Beta-Cells-1200x800-1.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Douglas Melton, Ph.D., holds up a vial of beta cells\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/02\/Douglas-Melton-Beta-Cells-1200x800-1.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/02\/Douglas-Melton-Beta-Cells-1200x800-1-800x533.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/02\/Douglas-Melton-Beta-Cells-1200x800-1-200x133.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/02\/Douglas-Melton-Beta-Cells-1200x800-1-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2021\/02\/Douglas-Melton-Beta-Cells-1200x800-1-400x267.jpg 400w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2014<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">C\u00e9lulas madre convertidas en c\u00e9lulas beta productoras de insulina<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">El doctor Doug Melton, investigador respaldado por Breakthrough T1D, desarrolla un protocolo innovador para convertir r\u00e1pidamente c\u00e9lulas madre humanas en c\u00e9lulas beta productoras de insulina en el laboratorio, acelerando significativamente el proceso de conversi\u00f3n. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/explora-investigacion\/cura-dt1\/terapias-celulares\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre nuestra investigaci\u00f3n en terapias celulares\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2014<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Primer ensayo cl\u00ednico en terapia de reemplazo celular<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Con el apoyo de Breakthrough T1D, ViaCyte inicia el primer ensayo cl\u00ednico que prueba una terapia de sustituci\u00f3n de c\u00e9lulas beta derivadas de c\u00e9lulas madre para la T1D. Los resultados iniciales demostraron que las c\u00e9lulas implantadas pueden producir insulina. <\/p>\n\t\t\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/06\/Stage-Graphic_EN_timeline-2.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"\" style=\"object-position: 47% 63%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/06\/Stage-Graphic_EN_timeline-2.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/06\/Stage-Graphic_EN_timeline-2-300x169.jpg 300w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2015<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Desarrollo del sistema de clasificaci\u00f3n por etapas de la T1D<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Breakthrough T1D lidera el esfuerzo para el desarrollo de un sistema de Clasificaci\u00f3n por Estadios que caracterice los estadios m\u00e1s tempranos de la T1D, lo que permite un seguimiento m\u00e1s preciso de la progresi\u00f3n de la enfermedad y un mejor dise\u00f1o de los ensayos cl\u00ednicos dirigidos a prevenirla.<\/p>\n\t\t\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2016<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Lanzamiento del Fondo T1D: Una empresa innovadora para la E1T<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Los voluntarios de Breakthrough T1D, deseosos de catalizar m\u00e1s inversi\u00f3n privada en terapias de curaci\u00f3n de la T1D, lanzan el primer fondo de filantrop\u00eda de riesgo del mundo dedicado a la diabetes tipo 1: el Fondo T1D: Un gran avance para la T1D. El Fondo T1D ha transformado el movimiento para curar la T1D creando un mercado de inversi\u00f3n que ha atra\u00eddo m\u00e1s de 800 millones de d\u00f3lares en capital riesgo privado. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/fondo-t1d\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el Fondo T1D\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"970\" height=\"500\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2016-1st-FDA-Approved-Artificial-Pancreas.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Young Girl Shows Off an Artificial Pancreas System\" style=\"object-position: 55% 51%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2016-1st-FDA-Approved-Artificial-Pancreas.jpg 970w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2016-1st-FDA-Approved-Artificial-Pancreas-800x412.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2016-1st-FDA-Approved-Artificial-Pancreas-200x103.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2016-1st-FDA-Approved-Artificial-Pancreas-768x396.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2016-1st-FDA-Approved-Artificial-Pancreas-400x206.jpg 400w\" sizes=\"auto, (max-width: 970px) 100vw, 970px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2016<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Primer sistema de p\u00e1ncreas artificial aprobado por la FDA<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">La FDA aprueba el sistema h\u00edbrido de AP de circuito cerrado MiniMed 670G de Medtronic, socio industrial de Breakthrough T1D, el primero aprobado para automatizar la dosificaci\u00f3n de insulina con el fin de reducir los niveles elevados de az\u00facar en sangre. Breakthrough T1D desempe\u00f1\u00f3 un papel integral en todas las etapas, financiando investigaciones cr\u00edticas y trabajando con la FDA para establecer un marco regulador. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/manejo-diario\/tecnologia-dt1\/sistemas-automaticos-de-administracion-de-insulina-y-bombas-de-insulina\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre los sistemas autom\u00e1ticos de administraci\u00f3n de insulina\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2018\/10\/Pregnancy_1200x675-1.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Pregnant Woman With a CGM\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2018\/10\/Pregnancy_1200x675-1.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2018\/10\/Pregnancy_1200x675-1-200x113.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2018\/10\/Pregnancy_1200x675-1-800x450.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2018\/10\/Pregnancy_1200x675-1-768x432.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2018\/10\/Pregnancy_1200x675-1-400x225.jpg 400w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2017<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Un estudio demuestra que el uso de MCG durante el embarazo mejora la salud de madres y beb\u00e9s<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Se publican los resultados del Ensayo de Monitorizaci\u00f3n Continua de la Glucosa en Mujeres con Diabetes Tipo 1 durante el Embarazo, un ensayo cofinanciado por Breakthrough T1D y los Institutos Canadienses de Investigaci\u00f3n Sanitaria (CIHR). Los resultados muestran que el uso de MCG durante y antes del embarazo mejora los resultados de salud tanto de las madres como de los beb\u00e9s, al tiempo que reduce los costes de hospitalizaci\u00f3n neonatal. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/recursos-dt1\/embarazo\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el embarazo y la T1D\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2018<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Un estudio demuestra que la medicaci\u00f3n para la tensi\u00f3n arterial puede preservar la producci\u00f3n de insulina en los reci\u00e9n diagnosticados<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">En un ensayo cl\u00ednico financiado por Breakthrough T1D, se demuestra que el Verapamilo, un medicamento ampliamente utilizado para la tensi\u00f3n arterial, preserva la producci\u00f3n de insulina en adultos con diabetes tipo 1 de inicio reciente, al preservar la funci\u00f3n de las c\u00e9lulas beta.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/verapamil-slows-type-1-diabetes-progression-newly-diagnosed-children-and-teens\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre este estudio\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2019<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">La terapia modificadora de la enfermedad retrasa la aparici\u00f3n de la T1D<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Se ha demostrado que el teplizumab, un anticuerpo monoclonal anti-CD3, retrasa el desarrollo de la T1D en personas de riesgo una media de dos a\u00f1os.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/?p=135646\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el teplizumab\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/div>\n\n\n<div class=\"wp-block-jdrf-timeline-year\">\n\t\t\t<h3 class=\"wp-block-jdrf-timeline-year__year\">los a\u00f1os 2020<\/h3>\n\t\n\t<div class=\"wp-block-jdrf-timeline-year__list\">\n\t\t\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/12\/tzield-1200x675-1-1.png\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Tzield, the first disease-modifying therapy for type 1 diabetes\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/12\/tzield-1200x675-1-1.png 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/12\/tzield-1200x675-1-1-800x450.png 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/12\/tzield-1200x675-1-1-200x113.png 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/12\/tzield-1200x675-1-1-768x432.png 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/12\/tzield-1200x675-1-1-400x225.png 400w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2022<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">La FDA aprueba el primer tratamiento modificador de la enfermedad para la diabetes tipo 1<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">La FDA aprueba Tzield\u2122 (teplizumab-mzwv), la primera terapia modificadora de la enfermedad (una terapia que puede ralentizar, detener o invertir la progresi\u00f3n de una enfermedad), para personas con riesgo de desarrollar una T1D. Breakthrough T1D lleva d\u00e9cadas apoyando este momento decisivo para la comunidad de personas con E1T. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/fda-approves-tzield-teplizumab-watershed-moment-t1d-community\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre esta terapia revolucionaria\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2022<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Un plan para producir insulina asequible<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Con el apoyo de Breakthrough T1D, el fabricante farmac\u00e9utico sin \u00e1nimo de lucro Civica anuncia planes para producir insulinas biosimilares de menor coste. Estas insulinas estar\u00e1n a disposici\u00f3n de cualquier persona, independientemente de su seguro, a un precio no superior a 30 $\/vial o 55 $\/caja de cinco plumas. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/insulin-affordability-yes-please-jdrf-joins-civica-make-low-cost-insulin-available-all-americans\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre nuestra asociaci\u00f3n con Civica\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2022\/09\/MicrosoftTeams-image.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"The Global T1D Index\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2022\/09\/MicrosoftTeams-image.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2022\/09\/MicrosoftTeams-image-800x533.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2022\/09\/MicrosoftTeams-image-200x133.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2022\/09\/MicrosoftTeams-image-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2022\/09\/MicrosoftTeams-image-400x267.jpg 400w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2022<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Lanzamiento del \u00cdndice T1D<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">El \u00cdndice T1D, una iniciativa dirigida por Breakthrough T1D, proporciona por primera vez una imagen completa de la T1D. Los datos del \u00edndice muestran la presencia y el crecimiento de la T1D en todos los pa\u00edses del mundo. El \u00edndice inspira la acci\u00f3n proporcionando una perspectiva poco habitual de los datos que hay detr\u00e1s de la T1D y de las estrategias que podr\u00edan salvar innumerables vidas y acelerar a\u00fan m\u00e1s las curas.  <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/?p=157246\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el \u00cdndice T1D, una herramienta \u00fanica que salva vidas\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2022<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Los autoanticuerpos se reconocen como indicadores del riesgo de T1D<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Los reguladores reconocen que los marcadores de la sangre, llamados autoanticuerpos, podr\u00edan utilizarse para detectar el riesgo de desarrollar una T1D, un esfuerzo que Breakthrough T1D ha defendido durante d\u00e9cadas para mejorar las posibilidades de identificar el estado de riesgo y reducir enfermedades peligrosas como la CAD, que a menudo se experimenta al diagnosticar una T1D.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/deteccion-temprana\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre la detecci\u00f3n precoz\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"970\" height=\"647\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2017-Beta-Cell-Replacement-Discovery.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Beta Cell Replacement Discovery\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2017-Beta-Cell-Replacement-Discovery.jpg 970w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2017-Beta-Cell-Replacement-Discovery-800x534.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2017-Beta-Cell-Replacement-Discovery-200x133.jpg 200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2017-Beta-Cell-Replacement-Discovery-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2020\/04\/2017-Beta-Cell-Replacement-Discovery-400x267.jpg 400w\" sizes=\"auto, (max-width: 970px) 100vw, 970px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2023<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">La FDA aprueba la primera terapia de sustituci\u00f3n celular<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">La FDA aprueba Lantidra\u2122, la primera terapia de sustituci\u00f3n de c\u00e9lulas beta. Esto establece una v\u00eda reguladora clave en la que Breakthrough T1D est\u00e1 trabajando para acelerar las terapias basadas en c\u00e9lulas madre, que no dependen de un suministro limitado de islotes de donantes fallecidos.  <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/explora-investigacion\/cura-dt1\/terapias-celulares\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tExplora nuestra investigaci\u00f3n en terapias celulares\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1538\" height=\"2048\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Woman Holding Her Baby With an AP System\" style=\"object-position: 54% 45%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby.jpg 1538w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby-225x300.jpg 225w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby-769x1024.jpg 769w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby-768x1023.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby-1154x1536.jpg 1154w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby-800x1065.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/10\/LivingT1D-MomBaby-1200x1598.jpg 1200w\" sizes=\"auto, (max-width: 1538px) 100vw, 1538px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2023<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Los sistemas de AP mejoran los resultados del embarazo<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Un estudio financiado por Breakthrough T1D descubre que los sistemas de PA reducen sustancialmente la glucemia materna, lo que beneficia a madres y beb\u00e9s. El estudio, publicado en la revista New England Journal of Medicine, recomienda un avance clave en las normas de atenci\u00f3n de la T1D: que todas las mujeres embarazadas con T1D tengan acceso a sistemas AP. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/recursos-dt1\/embarazo\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el embarazo y la T1D\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">2023<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Las terapias modificadoras de la enfermedad benefician a los reci\u00e9n diagnosticados<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Ensayos cl\u00ednicos innovadores apoyados por la T1D demuestran que tres terapias diferentes modificadoras de la enfermedad preservan la funci\u00f3n de las c\u00e9lulas beta y ralentizan la progresi\u00f3n de la T1D de nueva aparici\u00f3n. La traslaci\u00f3n al uso cl\u00ednico podr\u00eda agilizarse, ya que los tres medicamentos ya est\u00e1n aprobados para otras enfermedades o para retrasar la aparici\u00f3n de la T1D. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/what-drug-will-be-the-next-tzield\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tExplora nuestra investigaci\u00f3n financiada en terapias modificadoras de la enfermedad\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/breakthrought1d_logo_navy_bg.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Breakthrough T1D\" style=\"object-position: 51% 55%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/breakthrought1d_logo_navy_bg.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/breakthrought1d_logo_navy_bg-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/breakthrought1d_logo_navy_bg-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/breakthrought1d_logo_navy_bg-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/breakthrought1d_logo_navy_bg-800x533.jpg 800w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Junio de 2024<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Somos Breakthrough T1D<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Nos dimos cuenta de que necesit\u00e1bamos un nombre que reflejara qui\u00e9nes somos y hacia d\u00f3nde vamos. Era el momento de aprovechar el impulso generado por m\u00e1s de 50 a\u00f1os de investigaci\u00f3n, defensa y compromiso con la comunidad para crear una marca que reflejara qui\u00e9nes somos, de d\u00f3nde venimos y hacia d\u00f3nde vamos. Ahora somos Breakthrough T1D.  <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/sobre-breakthrought1d\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tDescubre m\u00e1s sobre nuestra nueva marca\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Junio de 2024<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Un avance en la diabetes tipo 1 impulsa la elaboraci\u00f3n de directrices de seguimiento<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Breakthrough T1D ha liderado una iniciativa para desarrollar las primeras directrices acordadas a nivel internacional sobre el seguimiento de ni\u00f1os, adolescentes y adultos que dan positivo en los anticuerpos contra la diabetes tipo 1, junto con las frecuencias de seguimiento recomendadas y las medidas que deben tomar los profesionales sanitarios cuando el riesgo de que la enfermedad evolucione hacia una diabetes tipo 1 sintom\u00e1tica es alto.\u202f <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/breakthrough-t1d-spearheads-formation-of-monitoring-guidelines\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre las directrices de seguimiento.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1969\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-scaled.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Project ACT Cell Therapies\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-scaled.jpg 2560w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-300x231.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-1024x788.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-768x591.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-1536x1182.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-2048x1575.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-800x615.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/11\/Scientific-1208378637-1200x923.jpg 1200w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Noviembre de 2024<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Se pone en marcha el proyecto ACT<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Las terapias celulares podr\u00edan curar a las personas con diabetes tipo 1. El Proyecto ACT es una iniciativa de Breakthrough T1D destinada a acelerar de forma espectacular el desarrollo de productos de terapia celular como cura para la diabetes tipo 1, mediante esfuerzos coordinados para impulsar al mismo tiempo la investigaci\u00f3n, el desarrollo, los aspectos normativos, el acceso y la adopci\u00f3n de estas terapias. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/proyecto-act\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el Proyecto ACT.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Noviembre de 2024<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Vertex pone en marcha un ensayo cl\u00ednico decisivo para una terapia con islotes derivados de c\u00e9lulas madre<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">El ensayo de fase 1\/2 de Vertex para el VX-880, una terapia con islotes derivada de c\u00e9lulas madre, pas\u00f3 a ser un ensayo pivotal de fase 3, en el que se inscribieron un total de 50 personas. Es la primera vez que un tratamiento escalable para algunas personas con diabetes tipo 1 entra en un ensayo cl\u00ednico de fase 3. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/vertex-launches-pivotal-trial-for-stem-cell-derived-islet-therapy\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre este ensayo cl\u00ednico clave.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/01\/resized-Scientific-1450273485-feature-1.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Cell Therapy Donor Islets\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/01\/resized-Scientific-1450273485-feature-1.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/01\/resized-Scientific-1450273485-feature-1-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/01\/resized-Scientific-1450273485-feature-1-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/01\/resized-Scientific-1450273485-feature-1-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/01\/resized-Scientific-1450273485-feature-1-800x533.jpg 800w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Enero de 2025<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Primero, la terapia celular: los islotes trasplantados funcionan sin inmunosupresores<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Sana Biotechnology, con el apoyo del T1D Fund: A Breakthrough T1D Venture, ha dado a conocer unos datos cl\u00ednicos muy importantes: la primera persona con diabetes tipo 1 que ha recibido islotes de un donante fallecido, modificados gen\u00e9ticamente para eludir el sistema inmunitario, est\u00e1 produciendo insulina sin necesidad de inmunosupresi\u00f3n.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/cell-therapy-first-transplanted-islets-working-without-immunosuppressives\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tLee m\u00e1s sobre el estudio de Sana.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1707\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-scaled.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Woman and Physician Discussing Medical Affairs\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-scaled.jpg 2560w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-1536x1024.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-2048x1365.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-800x533.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/05\/LivingT1D-1720223377-1200x800.jpg 1200w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Marzo de 2025<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Se ha creado una unidad innovadora de Asuntos M\u00e9dicos para la diabetes tipo 1<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Reducir la brecha entre el acceso a los tratamientos para la diabetes tipo 1 y su adopci\u00f3n es una prioridad de la misi\u00f3n de Breakthrough T1D. Hemos anunciado la creaci\u00f3n de una unidad de Asuntos M\u00e9dicos para abordar los numerosos retos que contribuyen a la lenta adopci\u00f3n de tratamientos innovadores para la diabetes tipo 1. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/medical-affairs-closing-the-gap-between-access-and-adoption\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre nuestra unidad de Asuntos M\u00e9dicos.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1247\" height=\"1168\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/11\/Barbie-CC25.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Young girl with type 1 diabetes shows off her new Barbie doll with type 1 diabetes\" style=\"object-position: 60% 17%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/11\/Barbie-CC25.jpg 1247w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/11\/Barbie-CC25-300x281.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/11\/Barbie-CC25-1024x959.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/11\/Barbie-CC25-768x719.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/11\/Barbie-CC25-800x749.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/11\/Barbie-CC25-1200x1124.jpg 1200w\" sizes=\"auto, (max-width: 1247px) 100vw, 1247px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Julio de 2025<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">La primera Barbie con diabetes tipo 1<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Breakthrough T1D y Mattel, Inc. presentan la primera mu\u00f1eca Barbie del mundo con diabetes tipo 1. Esta colaboraci\u00f3n pionera refleja un compromiso compartido para garantizar que los millones de personas que viven con diabetes tipo 1 sean vistas, escuchadas y se sientan empoderadas. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/first-barbie-doll-with-type-1-diabetes\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tLee m\u00e1s sobre la primera mu\u00f1eca Barbie con diabetes tipo 1.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Octubre de 2025<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Dos nuevos ensayos cl\u00ednicos para retrasar la diabetes tipo 1<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">A partir de los resultados de un prometedor estudio financiado por Breakthrough T1D, Eli Lilly pone en marcha dos nuevos ensayos cl\u00ednicos decisivos con baricitinib, un medicamento que ya est\u00e1 autorizado para otras enfermedades autoinmunes. Los ensayos evaluar\u00e1n si este comprimido, que se toma una vez al d\u00eda, puede retrasar la progresi\u00f3n de la diabetes tipo 1 de estadio 2 a estadio 3 o preservar las c\u00e9lulas beta en los casos de diabetes tipo 1 de estadio 3 reci\u00e9n diagnosticados. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/two-new-trials-baricitinib-to-delay-t1d\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tDescubre m\u00e1s sobre el estudio del baricitinib para retrasar la diabetes tipo 1.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Noviembre de 2025<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Se lanza ALIGN-T1D<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Breakthrough T1D, en colaboraci\u00f3n con otras organizaciones l\u00edderes en el \u00e1mbito de la diabetes tipo 1, pone en marcha ALIGN-T1D, una nueva alianza global que re\u00fane a l\u00edderes del \u00e1mbito filantr\u00f3pico, del sector privado y de la comunidad para reforzar las redes de atenci\u00f3n a la diabetes tipo 1 impulsadas por los gobiernos en pa\u00edses de renta baja y media, integrando el diagn\u00f3stico, el acceso a la insulina, el seguimiento y la educaci\u00f3n.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/es\/sobre\/presencia-mundial\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tDescubre m\u00e1s sobre nuestra presencia global.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/div>\n\n\n<div class=\"wp-block-jdrf-timeline-year\">\n\t\t\t<h3 class=\"wp-block-jdrf-timeline-year__year\">2026<\/h3>\n\t\n\t<div class=\"wp-block-jdrf-timeline-year__list\">\n\t\t\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/10\/Tzield-closeup.png\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Healthcare provider holding a vial of teplizumab (Tzield), the first FDA-approved disease-modifying therapy for type 1 diabetes\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/10\/Tzield-closeup.png 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/10\/Tzield-closeup-300x200.png 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/10\/Tzield-closeup-1024x683.png 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/10\/Tzield-closeup-768x512.png 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2025\/10\/Tzield-closeup-800x533.png 800w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Julio de 2026<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Tzield recibe la autorizaci\u00f3n para nuevos grupos de edad y estadios de la diabetes tipo 1 en EE. UU.<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Tzield cuenta con la autorizaci\u00f3n de la FDA para dos indicaciones ampliadas en EE. UU. En primer lugar, para retrasar la diabetes tipo 1 (DT1) en estadio 3 en personas de 1 a\u00f1o o m\u00e1s con DT1 en estadio 2; y, en segundo lugar, para preservar las c\u00e9lulas beta productoras de insulina en casos de DT1 en estadio 3 reci\u00e9n diagnosticados en j\u00f3venes de entre 8 y 17 a\u00f1os. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/tzield-approved-for-stage-3-t1d-in-the-u-s\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre la ampliaci\u00f3n de las autorizaciones de Tzield.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/06\/Ozempic-and-type-1-diabetes.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Woman prepares to give herself a semiglutide, or Ozempic, injection\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/06\/Ozempic-and-type-1-diabetes.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/06\/Ozempic-and-type-1-diabetes-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/06\/Ozempic-and-type-1-diabetes-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/06\/Ozempic-and-type-1-diabetes-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2023\/06\/Ozempic-and-type-1-diabetes-800x533.jpg 800w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Julio de 2026<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Se han puesto en marcha estudios de fase III sobre los GLP-1 y la diabetes tipo 1<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Lilly pone en marcha dos estudios de fase III para investigar el uso de un GLP-1 en personas con diabetes tipo 1 y obesidad. Breakthrough T1D lleva mucho tiempo defendiendo que se incluya a las personas con diabetes tipo 1 en los estudios sobre el GLP-1 y cree que esto podr\u00eda suponer importantes beneficios para la comunidad. <\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/ozempic-type-1-diabetes\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tDescubre m\u00e1s sobre nuestra investigaci\u00f3n sobre el GLP-1.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2500\" height=\"1667\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"Breakthrough T1D Clinical &amp; Research Congress Recap\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP.jpg 2500w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-1536x1024.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-2048x1366.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-800x533.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-1200x800.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-1920x1280.jpg 1920w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/10\/MARCOM-FY27-CRC-Conference-Deliverables-1200x800_RECAP-1440x960.jpg 1440w\" sizes=\"auto, (max-width: 2500px) 100vw, 2500px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Octubre de 2026<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Se celebra en Filadelfia el primer Congreso de Investigaci\u00f3n y Cl\u00ednica de la historia<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Breakthrough T1D ha organizado el primer Congreso Cl\u00ednico y de Investigaci\u00f3n, en el que la investigaci\u00f3n sobre terapia celular y los avances en los ensayos cl\u00ednicos han sido los protagonistas.<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/crc-2026-everything-you-need-to-know\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el Congreso Cl\u00ednico y de Investigaci\u00f3n de 2026.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\n<div data-motion-direction=right class=\"motion wp-block-jdrf-timeline-event\">\n\t\t\t<figure class=\"wp-block-jdrf-timeline-event__figure\">\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"7967\" height=\"5314\" src=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076.jpg\" class=\"wp-block-jdrf-timeline-event__img\" alt=\"A healthcare provider speaks to an older female patient with type 1 diabetes\" style=\"object-position: 50% 50%;\" srcset=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076.jpg 7967w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-300x200.jpg 300w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-1024x683.jpg 1024w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-768x512.jpg 768w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-1536x1025.jpg 1536w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-2048x1366.jpg 2048w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-800x534.jpg 800w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-1200x800.jpg 1200w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-1920x1281.jpg 1920w, https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2026\/09\/HCP-2205706076-1440x960.jpg 1440w\" sizes=\"auto, (max-width: 7967px) 100vw, 7967px\" \/>\t\t<\/figure>\n\t\n\t<div class=\"wp-block-jdrf-timeline-event__content\">\n\t\t\t\t\t<span class=\"wp-block-jdrf-timeline-event__byline\">Octubre de 2026<\/span>\n\t\t\n\t\t\t\t\t\t\t\t\t<h4 class=\"wp-block-jdrf-timeline-event__title\">Tegoprubart: Ampliaci\u00f3n de los trasplantes de islotes a la diabetes tipo 1 y la enfermedad renal<\/h4>\n\t\t\t\t\t\n\t\t\t\t\t<p class=\"wp-block-jdrf-timeline-event__description\">Se pone en marcha un nuevo ensayo cl\u00ednico financiado por Breakthrough T1D para investigar la inmunoterapia de Eledon Pharmaceuticals, el tegoprubart, junto con trasplantes de c\u00e9lulas de los islotes en personas con diabetes tipo 1 y enfermedad renal cr\u00f3nica (ERC).<\/p>\n\t\t\n\t\t\t\t\t<a\n\t\t\t\thref=\"https:\/\/www.breakthrought1d.org\/news-and-updates\/tegoprubart-islet-transplants-kidney-disease\/\"\n\t\t\t\tclass=\"wp-block-jdrf-timeline-event__link\"\n\t\t\t\t>\n\t\t\t\tM\u00e1s informaci\u00f3n sobre el ensayo cl\u00ednico de Eledon para la diabetes tipo 1 y la enfermedad renal cr\u00f3nica.\t\t\t<\/a>\n\t\t\n\t\t<span class=\"wp-block-jdrf-timeline-event__dot\"><\/span>\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/div>\n\n\t<\/div>\n<\/section>\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<div class=\"wp-block-group alignfull has-white-color has-navy-background-color has-text-color has-background has-link-color wp-elements-1 is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e50f5278 wp-block-columns-is-layout-flex has-2-columns\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 id=\"always-we-are-guided-by-a-single-purpose\" class=\"wp-block-heading has-h-3-font-size\">Siempre nos gu\u00eda un \u00fanico objetivo:<\/h2>\n\n\n\n<h3 id=\"as-we-drive-toward-curing-type-1-diabetes-we-help-make-everyday-life-better-for-the-people-who-face-it\" class=\"wp-block-heading has-h-4-font-size\">Mientras avanzamos hacia la curaci\u00f3n de la diabetes tipo 1, ayudamos a mejorar la vida cotidiana de las personas que se enfrentan a ella. <\/h3>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<div class=\"wp-block-buttons is-content-justification-right is-layout-flex wp-container-core-buttons-is-layout-d29d9d1d wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.breakthrought1d.org\/es\/sobre\/\">M\u00e1s informaci\u00f3n sobre Breakthrough T1D<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false,"raw":""},"excerpt":{"rendered":"<p>Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. Siempre nos gu\u00eda un \u00fanico objetivo: Mientras avanzamos hacia la curaci\u00f3n de la diabetes tipo 1, ayudamos a mejorar la vida cotidiana de las personas que se enfrentan a ella.<\/p>\n","protected":false},"author":1100,"featured_media":0,"parent":190903,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"ep_exclude_from_search":false,"publish_on_app_meta":"True","iawp_total_views":125,"footnotes":""},"class_list":["post-215758","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuestra historia - Breakthrough T1D<\/title>\n<meta name=\"description\" content=\"Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. Conoce nuestra historia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuestra historia - Breakthrough T1D\" \/>\n<meta property=\"og:description\" content=\"Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. Conoce nuestra historia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/\" \/>\n<meta property=\"og:site_name\" content=\"Breakthrough T1D\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/breakthrought1dHQ\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-13T18:41:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-fallbck-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@breakthrought1d\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/sobre\\\/nuestra-historia\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/sobre\\\/nuestra-historia\\\/\",\"name\":\"Nuestra historia - Breakthrough T1D\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#website\"},\"datePublished\":\"2024-10-17T14:03:05+00:00\",\"dateModified\":\"2026-11-13T18:41:03+00:00\",\"description\":\"Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. Conoce nuestra historia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/sobre\\\/nuestra-historia\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/sobre\\\/nuestra-historia\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/sobre\\\/nuestra-historia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qui\u00e9nes somos\",\"item\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/sobre\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nuestra historia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/\",\"name\":\"Breakthrough T1D\",\"description\":\"Improving Lives. Curing Type 1 Diabetes.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#organization\",\"name\":\"Breakthrough T1D\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"contentUrl\":\"https:\\\/\\\/www.breakthrought1d.org\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/BT1D-favi.png\",\"width\":400,\"height\":400,\"caption\":\"Breakthrough T1D\"},\"image\":{\"@id\":\"https:\\\/\\\/www.breakthrought1d.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/breakthrought1dHQ\",\"https:\\\/\\\/x.com\\\/breakthrought1d\",\"https:\\\/\\\/www.youtube.com\\\/@breakthrought1d\",\"https:\\\/\\\/www.instagram.com\\\/breakthrought1d\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@breakthrought1dhq\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuestra historia - Breakthrough T1D","description":"Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. Conoce nuestra historia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/","og_locale":"es_ES","og_type":"article","og_title":"Nuestra historia - Breakthrough T1D","og_description":"Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. Conoce nuestra historia.","og_url":"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/","og_site_name":"Breakthrough T1D","article_publisher":"https:\/\/www.facebook.com\/breakthrought1dHQ","article_modified_time":"2026-11-13T18:41:03+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-fallbck-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@breakthrought1d","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/","url":"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/","name":"Nuestra historia - Breakthrough T1D","isPartOf":{"@id":"https:\/\/www.breakthrought1d.org\/es\/#website"},"datePublished":"2024-10-17T14:03:05+00:00","dateModified":"2026-11-13T18:41:03+00:00","description":"Desde nuestra fundaci\u00f3n en 1970, Breakthrough T1D ha desempe\u00f1ado un papel fundamental en todos los grandes hitos de la diabetes tipo 1. Conoce nuestra historia.","breadcrumb":{"@id":"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.breakthrought1d.org\/es\/sobre\/nuestra-historia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.breakthrought1d.org\/es\/"},{"@type":"ListItem","position":2,"name":"Qui\u00e9nes somos","item":"https:\/\/www.breakthrought1d.org\/es\/sobre\/"},{"@type":"ListItem","position":3,"name":"Nuestra historia"}]},{"@type":"WebSite","@id":"https:\/\/www.breakthrought1d.org\/es\/#website","url":"https:\/\/www.breakthrought1d.org\/es\/","name":"Breakthrough T1D","description":"Improving Lives. Curing Type 1 Diabetes.","publisher":{"@id":"https:\/\/www.breakthrought1d.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.breakthrought1d.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.breakthrought1d.org\/es\/#organization","name":"Breakthrough T1D","url":"https:\/\/www.breakthrought1d.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.breakthrought1d.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","contentUrl":"https:\/\/www.breakthrought1d.org\/wp-content\/uploads\/2024\/06\/BT1D-favi.png","width":400,"height":400,"caption":"Breakthrough T1D"},"image":{"@id":"https:\/\/www.breakthrought1d.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/breakthrought1dHQ","https:\/\/x.com\/breakthrought1d","https:\/\/www.youtube.com\/@breakthrought1d","https:\/\/www.instagram.com\/breakthrought1d\/","https:\/\/www.tiktok.com\/@breakthrought1dhq"]}]}},"_links":{"self":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages\/215758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/users\/1100"}],"replies":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/comments?post=215758"}],"version-history":[{"count":2,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages\/215758\/revisions"}],"predecessor-version":[{"id":233529,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages\/215758\/revisions\/233529"}],"up":[{"embeddable":true,"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/pages\/190903"}],"wp:attachment":[{"href":"https:\/\/www.breakthrought1d.org\/es\/wp-json\/wp\/v2\/media?parent=215758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}